The Indian Pharma Market (IPM) has been valued at Rs 6100 crores in May 2013. It has seen a growth of 9.9 per cent during May. For the month of May 2013, amongst the top 10 corporates, Zydus has seen a growth of 24.3 per cent, followed by Sun Pharma at 21.2 per cent and Ranbaxy at 20.2 per cent. 23 corporates have crossed the growth of IPM for the month of May amongst the top 50.
| With Bonus Units at Full Value | ||||||||
| Val in Crs | Rank | MAT May -13 | May-13 | |||||
| COMPANY | MAT | MTH | Val (Cr) | MS% | GR% | GR% | MS% | GR% |
|
IPM
|
71774 | 100.00 | 10.6 | 6069 | 100.00 | 9.8 | ||
|
Sun Pharma
|
1
|
1
|
3608 | 5.03 | 20.9 | 327 | 5.39 | 21.2 |
|
Cipla
|
2
|
2
|
3576 | 4.98 | 6.0 | 307 | 5.06 | 12.1 |
|
Glaxo
|
3
|
5
|
3201 | 4.46 | 6.7 | 248 | 4.08 | -5.1 |
|
Ranbaxy
|
4
|
3
|
2983 | 4.16 | 7.9 | 256 | 4.21 | 20.2 |
|
Zydus Cadila
|
5
|
4
|
2961 | 4.13 | 23.3 | 253 | 4.17 | 25.3 |
|
Abbott HC
|
6
|
6
|
2732 | 3.81 | 7.6 | 222 | 3.66 | 11.0 |
|
Mankind
|
7
|
7
|
2597 | 3.62 | 20.2 | 215 | 3.55 | 8.2 |
|
Lupin
|
8
|
8
|
2210 | 3.08 | 14.2 | 189 | 3.11 | 14.4 |
|
Alkem
|
9
|
9
|
2190 | 3.05 | 11.8 | 185 | 3.05 | 15.8 |
|
Macleods
|
10
|
10
|
1846 | 2.57 | 18.1 | 156 | 2.57 | 12.8 |
|
Intas
|
11
|
11
|
1781 | 2.48 | 18.8 | 154 | 2.54 | 15.7 |
|
Pfizer
|
12
|
13
|
1714 | 2.39 | 12.1 | 136 | 2.25 | -0.3 |
|
Aristo
|
13
|
12
|
1651 | 2.30 | 9.8 | 139 | 2.28 | 7.4 |
|
Dr. Reddys
|
14
|
14
|
1583 | 2.20 | 12.1 | 136 | 2.24 | 13.0 |
|
Sanofi-Aventis
|
15
|
15
|
1436 | 2.00 | 9.0 | 120 | 1.98 | 4.0 |
|
Glenmark
|
16
|
18
|
1430 | 1.99 | 17.0 | 116 | 1.91 | 14.5 |
|
Abbott
|
17
|
16
|
1418 | 1.98 | 6.9 | 117 | 1.93 | 1.7 |
|
IPCA
|
18
|
19
|
1298 | 1.81 | 15.8 | 112 | 1.84 | 15.8 |
|
USV
|
19
|
17
|
1284 | 1.79 | 20.9 | 116 | 1.91 | 18.8 |
|
Micro Lab
|
20
|
21
|
1271 | 1.77 | 5.7 | 106 | 1.74 | 9.0 |
Amongst the top 50 corporates, Bharat Serums has the highest growth of 52.8 per cent followed by AstraZeneca at 39.9 per cent and Eris at 28.5 per cent. Amongst the 11-20 ranked companies USV has shown high growth at 18.8 per cent followed by Ipca at 15.8 per cent and Intas at 15.7 per cent. Akumentis breaks into top 50 amongst the corporates. Amongst the upcoming corporates Corona Remedies has seen a growth of 171.6 per cent, Eris at 28.5 per cent and Akumentis at 24.2 per cent. Astra comes to positive growth during May with 39.9 per cent. Centaur has entered the `200 crores club and Micro has crossed Rs 1300 crores on MAT basis.
|
Val in Crs
|
RANK MAT
|
With Bonus in Crs
|
|||||
|
Super Group
|
SV
|
AV
|
BV
|
MAT May13
|
GR%
|
Mth May13
|
GR%
|
|
IPM
|
71774
|
10.6
|
6069
|
9.8
|
|||
|
ANTI-INFECTIVES
|
1
|
1
|
1
|
12666
|
8.5
|
996
|
8.7
|
|
CARDIAC
|
2
|
2
|
10
|
8839
|
13.1
|
776
|
12.9
|
|
GASTRO INTESTINAL
|
3
|
3
|
3
|
8178
|
11.8
|
756
|
9.0
|
|
VITAMINS / MINERALS / NUTRIENTS
|
4
|
4
|
7
|
6344
|
11.2
|
554
|
7.1
|
|
RESPIRATORY
|
5
|
5
|
4
|
5429
|
7.5
|
382
|
9.7
|
|
PAIN / ANALGESICS
|
6
|
6
|
5
|
5309
|
7.9
|
440
|
6.8
|
|
ANTI DIABETIC
|
7
|
7
|
16
|
4671
|
14.6
|
414
|
12.5
|
|
GYNAECOLOGICAL
|
8
|
9
|
2
|
4658
|
8.0
|
400
|
5.1
|
|
NEURO / CNS
|
9
|
8
|
12
|
4383
|
11.4
|
382
|
13.2
|
|
DERMA
|
10
|
10
|
9
|
3770
|
11.5
|
322
|
11.7
|
|
OPHTHAL / OTOLOGICALS
|
11
|
11
|
15
|
1286
|
11.3
|
114
|
5.8
|
|
HORMONES
|
12
|
12
|
14
|
1242
|
16.3
|
104
|
12.2
|
From therapy perspective nine therapies have outgrown the IPM growth. The anti-infective market has a growth of 8.7 per cent whereas respiratory market is at 10.4 per cent growth. The anti-diabetic market has seen a growth at 12.5 per cent and Cardiac at 12.9 per cent in chronic business. Amongst the top 10 therapies, Neuro/ CNS market has shown the highest growth at 13.2 per cent.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech.
AWACS in AIOCD AWACS stands for Advanced Working, Action & Correction System – reflecting the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information. Accurate and faster information flows from the market will help clients grow topline and bottom-line.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val(Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage
For more information, visit http://www.aiocd.net